A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

CompletedOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

September 9, 2024

Study Completion Date

September 9, 2024

Conditions
Hereditary Angioedema (HAE)
Trial Locations (19)

1090

Medical University of Vienna, Vienna

4031

Universitätsspital Basel, Basel

6000

Luzerner Kantonsspital LUKS, Lucerne

10117

Charité - Universitätsmedizin Berlin, Berlin

20157

ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milan

23538

Universitatsklinikum Schleswig-Holstein, Lübeck

31048

Bnai Zion Medical Center, Haifa

35128

Azienda Ospedale Università Padova, Padua

40225

Universitatsklinikum Dusseldorf, Düsseldorf

48149

Universitätsklinikum Münster, Münster

52621

Sheba Medical Center - PPDS, Ramat Gan

60590

Klinikum der Johann-Wolfgang Goethe-Universitat, Frankfurt am Main

64546

Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf

80131

Azienda Ospedaliera Universitaria Federico II, Napoli

81675

Klinikum rechts der Isar der Technischen Universität München, München

89075

Universitätsklinikum Ulm, Ulm

90806

Al-Rashed Allergy Center, Kuwait City

08907

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

08035

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Shire

INDUSTRY